Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.3 AUD | +0.10% | -5.39% | -22.71% |
03:34am | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Feb. 29 | Neuren Pharmaceuticals Limited Provides Sales Guidance for the First Quarter and Full Year 2024 | CI |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Commercial Products
100.0
%
| - | - | 232 | 100.0 % | - |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| - | - | 232 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jon Pilcher
CEO | Chief Executive Officer | 58 | 13-08-18 |
Lauren Frazer
DFI | Director of Finance/CFO | - | 20-07-31 |
Liza Squires
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-07 |
James Shaw
COO | Chief Operating Officer | - | 13-07-31 |
Larry Glass
CTO | Chief Tech/Sci/R&D Officer | - | 03-12-31 |
Gerry Zhao
PRN | Corporate Officer/Principal | - | 22-01-31 |
Nancy E. Jones
PRN | Corporate Officer/Principal | - | 13-01-08 |
Clive Blower
PRN | Corporate Officer/Principal | - | 14-08-24 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 02-03-04 | |
Dianne Angus
BRD | Director/Board Member | 63 | 18-07-04 |
Jenny Lee Harry
BRD | Director/Board Member | - | 18-07-04 |
Jon Pilcher
CEO | Chief Executive Officer | 58 | 13-08-18 |
Larry Glass
CTO | Chief Tech/Sci/R&D Officer | - | 03-12-31 |
Patrick Davies
CHM | Chairman | 57 | 18-07-04 |
Joe Basile
BRD | Director/Board Member | - | 23-03-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 129,665,676 | 107,568,831 ( 82.96 %) | 2,400,000 ( 1.851 %) | 82.96 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.71% | 1.58B | |
+25.46% | 659B | |
+25.73% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+6.40% | 215B | |
+7.85% | 210B | |
-5.93% | 200B | |
-8.79% | 149B |
- Stock Market
- Equities
- NEU Stock
- Company Neuren Pharmaceuticals Limited